Business Context and Reporting Period
Kura Oncology, Inc. filed this Form 8-K on May 19, 2021, to report the termination of a material definitive agreement. The company is incorporated in Delaware and trades on the Nasdaq Global Select Market under the symbol KURA.
Key Financial Metrics
This filing does not report revenue, profit, or operating cash flow. The primary financial metric disclosed is the debt payoff amount.
- Debt Payoff: Approximately $6.6 million paid in full to Silicon Valley Bank.
- Payoff Components: Included principal, interest, and fees.
- Liquidity Impact: The payment eliminated all commitments and obligations under the Loan and Security Agreement dated November 1, 2018.
Material Changes
The material change reported is the complete termination of the Loan and Security Agreement with Silicon Valley Bank. Prior to this date, the company held outstanding obligations under this facility. As of May 19, 2021, the company has no remaining debt or obligations to the lender under this specific agreement.
Outlook and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of new risks. The transaction resolves a prior contingency related to the repayment of the loan facility.
Investor Verification Checklist
- Verify the exact breakdown of the $6.6 million payoff between principal, accrued interest, and prepayment fees.
- Review the company's most recent Form 10-Q (filed May 6, 2021) for the remaining cash balance post-payment.
- Confirm if the company has secured alternative financing or if this payoff was funded entirely by existing cash reserves.